Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Study on PD-L1 Expression in NSCLC Patients and Related Influencing Factors in the Real World.

Computational and mathematical methods in medicine - 1 Jan 2021

Zhu Yefei, Lin Shuangxiang, Wang Yueping, Shen Bingxiao, Lin Ling, Wang Liangxing, He Susu

Abstract excerpt

PD-L1 is one of the current biomarkers for immune checkpoint inhibitor (ICI) therapy in patients with non-small-cell lung cancer. However, the expression of PD-L1 in the real world and its related influencing factors remain unclear. We want to observe the expression of PD-L1 in the real world and study the related influencing factors through the collection and analysis of clinical data. R software (version 4.0)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Computational Biology

Share to ErbB Receptors

Share to Immunohistochemistry

Share to Immunotherapy

Share to Lung Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 34992670
DOI: 10.1155/2021/3273347
PMCID: PMC8727119

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Study on PD-L1 Expression in NSCLC Patients and Related Influencing Factors in the Real World.PMID 34992670Read ↗

Mutation mapping of PD-L1 expression in advanced non-small cell lung cancer: A real-world retrospective cohort studySemantic proximity Read ↗

[A Real-world Study on the Expression Characteristics of PD-L1 in Patients with Advanced EGFR Positive NSCLC and Its Relationship with the Therapeutic Efficacy of EGFR-TKIs].Semantic proximity Read ↗

Who Will Benefit Most From PD-L1 Detection and Immunotherapy in Non-small Cell Lung Cancer?Semantic proximity Read ↗

Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.Semantic proximity Read ↗

PD-L1 Expression in NSCLC: Clouds in a Bright SkySemantic proximity Read ↗

[Research Progress of Anti-PD-1/PD-L1 Therapy for Non-small Cell Lung Cancer with EGFR Mutation].Semantic proximity Read ↗

PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective.Semantic proximity Read ↗

[Advances in the Influence of EGFR Mutation on the PD-L1 Expression in Non-small Cell Lung Cancer].Semantic proximity Read ↗

Prognostic impact of PD-L1 expression in surgically resected EGFR-mutant lung adenocarcinoma: A real-world database study in Japan (CReGYT-01 EGFR study).Semantic proximity Read ↗

Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.Semantic proximity Read ↗

PD-L1 as a biomarker in NSCLC: challenges and future directionsSemantic proximity Read ↗

[A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.